TC-510 by TCR2 Therapeutics for Malignant Pleural Mesothelioma: Likelihood of Approval
TC-510 is under clinical development by TCR2 Therapeutics and currently in Phase II for Malignant Pleural Mesothelioma.
Source: pharmaceutical-technology.com
Malignant Pleural News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Malignant Pleural. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Malignant Pleural Today - Breaking & Trending Today
A Bird's Eye View Of Eagle Pharma
Shares of Eagle Pharmaceuticals Inc. (EGRX) are down 67% from their 52-week high of $40.85, recorded last November, and trade around $13..
Source: rttnews.com
Malignant Pleural Effusion Market value of US$ 4.5 Billion in 2023
The global malignant pleural effusion market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by registering a CAGR of 6% in the forecast period 2023-2033. The increasing incidence of pleural effusion disease and rising awareness of adva...
Source: pharmiweb.com
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
/PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The...
Source: prnewswire.com